News >

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

Wayne Kuznar
Published: Tuesday, Jan 23, 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin (BBI608) with the PD-1 inhibitor pembrolizumab (Keytruda) showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer (mCRC).

The napabucasin/pembrolizumab combination showed “an efficacy signal and might evoke immunity in MSS mCRC, which will be confirmed by the ongoing phase II part,” the investigators concluded.
Kawazoe A, Kuboki Y, Komatsu Y, et al. Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503. Presented at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA. Abstract 760.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x